The following table details the trading activities
(stock purchases, stock sales, and stock option exercises)
the Securities and Exchange Commission (SEC)
by insider Howton David T since year 2005.
The trader's CIK number is 1529297.
At the time of this reporting, Howton David T is the SVP, General Counsel of Sarepta Therapeutics, Inc. .
(stock ticker symbol SRPT).
See this page for all insider trading activities at Sarepta Therapeutics, Inc. .
|Trade Date||Symbol||Company Name (Issuer)||Trade Type||Shares||Price ($)||Value ($)|
|2019-02-01||SRPT||Sarepta Therapeutics, Inc.||Option Ex||21,500||17.09||367,435|
|2019-02-01||SRPT||Sarepta Therapeutics, Inc.||Sale||30,000||140.00||4,200,000|
|2018-07-16||SRPT||Sarepta Therapeutics, Inc.||Option Ex||50,000||13.77||688,650|
|2018-07-16||SRPT||Sarepta Therapeutics, Inc.||Sale||50,000||136.46||6,823,000|
|2018-05-22||SRPT||Sarepta Therapeutics, Inc.||Option Ex||5,319||.00||0|
|2018-03-15||SRPT||Sarepta Therapeutics, Inc.||Option Ex||2,500||17.15||42,882|
|2017-08-03||SRPT||Sarepta Therapeutics, Inc.||Option Ex||10,639||.00||0|
|2017-07-20||SRPT||Sarepta Therapeutics, Inc.||Option Ex||25,000||13.71||342,750|
|2017-07-21||SRPT||Sarepta Therapeutics, Inc.||Option Ex||1,000||18.78||18,780|
|2017-07-20||SRPT||Sarepta Therapeutics, Inc.||Sale||25,000||41.00||1,025,000|
|2016-11-09||SRPT||Sarepta Therapeutics, Inc.||Option Ex||1,000||23.85||23,850|
|2016-09-22||SRPT||Sarepta Therapeutics, Inc.||Option Ex||7,000||13.90||97,300|
|2016-09-22||SRPT||Sarepta Therapeutics, Inc.||Sale||7,000||60.00||420,000|
|2016-09-19||SRPT||Sarepta Therapeutics, Inc.||Sale||9,304||50.00||465,200|
|2016-09-19||SRPT||Sarepta Therapeutics, Inc.||Option Ex||8,000||13.90||111,200|
|2011-09-01||VRTX||Vertex Pharmaceuticals Inc / Ma||Sale||328||44.29||14,527|
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Howton David T (SVP, General Counsel of Sarepta Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.